Cybin Inc.

Cybin Inc. (NEO: CYBN) (NYSE AMERICAN: CYBN), a biopharmaceutical company focused on psychedelics for mental health, announced Tuesday that the first two participants have been dosed in its Phase 1/2a trial evaluating CYB003 for the treatment of the major depressive disorder (MDD). CYB003 is...

Cybin Inc. (NYSE:CYBN) and Kernel, two companies that undertook a joint feasibility study to evaluate the effects ketamine has on blood flow in the brain in late March, announced their results. In a video shared by Kernel, the company’s CEO and founder, Bryan...

Psychedelic therapy company, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), recently announced it was awarded a grant for the first psychedelic treatment clinic at New York City’s Lenox Hill Hospital with which it will provide care to marginalized and underserved communities on Manhattan...

Get into psychedelics now. That's according to Michael "Zappy" Zapolin, a former Bear Stearns VP turned psychedelics advocate and filmmaker. Zappy's call to invest comes as psychedelics make a continued push towards credibility on the medical, legal and business...